Open AccessA large, single‐center, real‐world study of clinicopathological characteristics and treatment in advanced ALK ‐positive non‐small‐cell lung cancer
Author(s) -
Chen Gang,
Chen Xi,
Zhang Yaxiong,
Yan Fang,
Fang Wenfeng,
Yang Yunpeng,
Hong Shaodong,
Miao Siyu,
Wu Manli,
Huang Xiaodan,
Luo Youli,
Zhou Cong,
Gong Run,
Huang Yan,
Zhou Ningning,
Zhao Hongyun,
Zhang Li
Publication year - 2017
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.1059
Subject(s) - crizotinib , anaplastic lymphoma kinase , medicine , lung cancer , alk inhibitor , oncology , brain metastasis , chemotherapy , pleural effusion , single center , metastasis , malignant pleural effusion , performance status , cancer
Crizotinib has achieved astonishing success in advanced non‐small‐cell lung cancer ( NSCLC ) patients harboring anaplastic lymphoma kinase ( ALK ) rearrangement. However, no real‐world studies described the clinicopathological characteristics and treatment of such patients in China. Patients were consecutively collected from Sun Yat‐sen University Cancer Center. Chi‐square test was applied to explore the relationship between ALK fusion status and metastasis sites. Kaplan–Meier methods and multivariable analyses were used to estimate progression‐free survival ( PFS ). A total of 291 advanced NSCLC patients ( ALK (+), N = 97; both ALK & epidermal growth factor receptor ( EGFR ) (‐), N = 194) were enrolled. The occurrence of brain metastasis in ALK ‐positive patients was significantly higher than double‐negative ones both at baseline (26.5% vs. 16.5%, P = 0.038) and during treatment (25.8% vs. 11.9%, P = 0.003), but opposite for pleural effusion (6.2% vs. 26.9%, P < 0.001 at baseline; 3.1% vs. 10.3%, P = 0.031 during treatment). ALK ‐positive patients of 53.6% used crizotinib, whereas others only received chemotherapy (37.1%) or supportive care (9.3%). Usage of crizotinib prolonged PFS compared with chemotherapy in ALK ‐positive patients (median PFS 17.6 m vs. 4.8 m, P < 0.001). ALK ‐positive NSCLC had more brain metastasis and less pleural effusion than double‐negative ones. Crizotinib showed better PFS than chemotherapy in advanced ALK ‐positive NSCLC at any line. However, half advanced ALK ‐positive patients never received crizotinib, which was grim and need improving.